Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies

OBJECTIVES:

- To obtain high-quality, clinically annotated tissue from patients with human
immunodeficiency virus (HIV)-1 malignancy.

- To study clinical, genetic, and immunologic parameters that have prognostic significance
and/or are involved in the initiation and progression of HIV-1 malignancies, including
complete genomic sequence determination of HIV-associated diffuse large B-cell
lymphomas, lung cancer, anal cancer, and cervical cancer.

OUTLINE: This is a multicenter study.

Patients undergo tumor, lymph node, bone marrow, or skin biopsy, and peripheral blood
mononuclear cells collection. Samples are submitted to the AIDS Malignancy Consortium (AMC)
Biorepository and transferred to the AIDS and Cancer Specimen Resource (ACSR). Samples are
then analyzed by the Genome Science Center of British Columbia (GSC-BC) and the HIV+ Tumor
Molecular Characterization Project (HTMCP) for full genomic sequencing analysis that may
include, but are not limited to, array-based gene expression profiling, comparative genome
hybridization, and single nucleotide polymorphism studies by flow cytometry, cytogenetics,
and molecular studies. Patients' clinical data, demographics, and treatment given are also
collected prospectively in order to record treatment outcome and toxicity.

Patients are followed up at 6 months, 1 year, and 2 years for data-reporting purposes.

DISEASE CHARACTERISTICS:

- Participants must have a diagnosis of a malignancy or clinical findings suggestive of
a possible HIV-associated malignancy of one of three types:

- Diffuse large B-cell lymphoma

- Non-small cell lung malignancy

- Cervical cancer

- The presence of any of the following conditions will exclude a participant from study
enrollment:

- Absence of sufficient diagnostic tumor-biopsy tissue material to meet the
protocol requirements for baseline specimen submission (minimum specimen size of
10 x 10 x 2 mm); repeat tumor biopsy will not be performed solely to meet the
protocol specimen-collection requirements

- Participants whose biopsies, for the purpose of this protocol, show a diagnosis
of anal intraepithelial neoplasia or cervical intraepithelial neoplasia

- Prior treatment for the study malignancy (including neo-adjuvants), since
treatment can affect the mutational spectra of tumors

- HIV infection based on serologic documentation of HIV infection at any time prior to
study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA),
positive western blot, or any other Food and Drug Administration (FDA)-approved
(licensed) HIV test; alternatively, this documentation may include a record that
another physician has documented that the patient has HIV based on prior ELISA and
western blot, or other approved diagnostic tests

PATIENT CHARACTERISTICS:

- Participants must be willing and able to sign an IRB-approved informed consent
document

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics